Researchers at Fred Hutch Cancer Center identified a substantial increase over the past decade in the proportion of patients with cancer in the U.S. who participate in pharmaceutical industry ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

The nation’s health department has distributed 900 million free at-home COVID tests since winter 2021. It restarted the program Thursday.

The FDA has approved at-home self- or caregiver-administration of FluMist (influenza vaccine live, intranasal).

The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...

PARP Inhibitor Market is projected to expand substantially, surpassing USD 16,153.50 million by 2034 at a CAGR of 8.70%.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp. (TM), AstraZeneca ...

The COVID pandemic is ongoing, but scientists are on alert for any pathogen that might lead to another global outbreak of ...

AstraZeneca AZN stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca ...